Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)

v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Aug. 31, 2024
USD ($)
shares
Jul. 31, 2024
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Number of Operating Segments | segment             2      
Payments in Investment             $ 15,000 $ 0    
Gain (loss) on equity method investment         $ 46 $ (1,914) 420 (4,204)    
Positions eliminated during the period as a percentage           4.00%        
Impairment charges related to the disposal group             0 6,038    
Number of expired vested stock options (in shares) | shares   794,400                
Total net pre-tax value of options that expired   $ 32,000                
Litigation charges         1,400 $ 0 1,700 0    
Accrued litigation         0   0   $ 0  
Protein Sciences                    
Goodwill attributable to disposal group held for sale           $ 1,400   $ 1,400    
Inventory, sold as part of disposal group         8,000   8,000      
Promissory note related to sale of inventory of disposal group         6,000   6,000      
Pre-tax restructuring charges                 200 $ 1,700
Protein Sciences | Fiscal Year 2024 Restructuring Actions                    
Impairment charges related to the disposal group             0      
Protein Sciences | Current Assets, Held For Sale | Fiscal Year 2024 Restructuring Actions                    
Property, plant and equipment attributable to disposal group held for sale         $ 1,000   $ 1,000      
Wilson Wolf Corporation                    
Payments in Investment $ 232,000     $ 25,000            
Investment percentage 19.90%                  
Forward Contract, Milestone, Multiple for Total Expected Payments         4.4   4.4      
Gain (loss) on equity method investment             $ 400      
Investment amount         $ 241,000   241,000      
Wilson Wolf Corporation | First Part of Forward Contract                    
Forward Contract, Milestone, Annual Revenue Required         92,000   92,000      
Forward Contract, Milestone, Annual EBITDA         55,000   55,000      
Wilson Wolf Corporation | Second Part of Forward Contract                    
Forward Contract, Milestone, Annual Revenue Required         226,000   226,000      
Forward Contract, Milestone, Annual EBITDA         136,000   136,000      
Forward Contract, Additional Investment         1,000,000   1,000,000      
Spear Bio                    
Payments in Investment     $ 15,000              
Spear Bio | Other assets                    
Long-term investments         $ 15,000   $ 15,000      
Selling, General and Administrative Expenses | Protein Sciences | Fiscal Year 2024 Restructuring Actions                    
Asset Impairment Charges                 $ 22,000